Moreover, FOXD2-AS1 was upregulated in cisplatin resistance non-small cell lung cancer (NSCLC), and the knockdown of FOXD2-AS1 improved NSCLC cells drug sensitivity by reducing cell growth, cell migration, and cell invasion through miR-185-5p/sine oculis homeobox homolog 1 (SIX1) axis [11]. Here, FOXD2 is linked to non-small cell lung carcinoma.